Thermo Fisher Scientific (TMO) Liabilities and Shareholders Equity (2009 - 2026)

Thermo Fisher Scientific (TMO) has reported Liabilities and Shareholders Equity for 18 consecutive years, with $113.3 billion the latest figure, recorded in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $113.3 billion, up 14.38% year-over-year; the trailing twelve-month figure through Mar 2026 was $427.9 billion (up 8.26% YoY), and the FY2025 annual result was $110.3 billion, up 13.38% from the prior year.
• Liabilities and Shareholders Equity was $113.3 billion for Q1 2026 at Thermo Fisher Scientific, up from $110.3 billion in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $113.3 billion in Q1 2026 and troughed at $90.5 billion in Q4 2022.
• Average Liabilities and Shareholders Equity over 5 years is $98.6 billion, with a median of $97.3 billion recorded in 2024.
• Year-over-year, Liabilities and Shareholders Equity jumped 40.67% in 2022 and declined 1.42% in 2024.
• Over 5 years, Liabilities and Shareholders Equity stood at $97.2 billion in 2022, then increased by 1.62% to $98.7 billion in 2023, then declined by 1.42% to $97.3 billion in 2024, then rose by 13.38% to $110.3 billion in 2025, then rose by 2.66% to $113.3 billion in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $113.3 billion in Q1 2026, $110.3 billion in Q4 2025, and $103.0 billion in Q3 2025.